Skip to main content

Azamian Bobak R.'s Form 4 filing

Tarsus Pharmaceuticals, Inc. (TARS) · filed Mar 19, 2024

Accession no.
0001819790-24-000045
Filed
Mar 19, 2024
Trade date
Mar 15-18, 2024
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market sales total $318.7K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Azamian Bobak R.CIK 0001827672Director, Officer (President/CEO and Board Chair)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 15, 2024Common StockMOption exerciseAcquired+28,274–F1–36,871Direct
Mar 18, 2024Common StockSSaleDisposed−10,415$30.60−$318,69926,456Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 15, 2024Common StockMOption exerciseDisposed−11,299$0.00$022,599Direct
Mar 15, 2024Common StockMOption exerciseDisposed−16,975$0.00$050,925Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)